Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466397 | 1.00 | PDE4D (0.50) | PDE4DPDE4BGRM5ITGB2ICAM1 | |
| SCHEMBL8027521 | 0.95 | PDE4D (0.52) | PDE4DPDE4BGRM5HCRTR1HCRTR2 | |
| Acetic Acid SCHEMBL3466976 | 0.93 | PDE4D (0.50) | PDE4DPDE4BGRM5HCRTR1HCRTR2 | |
| SCHEMBL3466979 | 0.85 | PDE4D (0.49) | PDE4DPDE4BGRM5HCRTR1HCRTR2 | |
| SCHEMBL3466926 | 0.85 | ITGB2 (0.40) | GRM5ITGB2ICAM1ITGALHCRTR1 | |
| SCHEMBL3466737 | 0.85 | ITGB2 (0.40) | GRM5ITGB2ICAM1ITGALHCRTR1 | |
| SCHEMBL3466742 | 0.85 | ITGB2 (0.40) | GRM5ITGB2ICAM1ITGALHCRTR1 | |
| SCHEMBL4330740 | 0.81 | PDE4B (0.53) | PDE4DPDE4B | |
| SCHEMBL3466221 | 0.80 | GRM5 (0.37) | PDE4DPDE4BGRM5ITGB2ICAM1 | |
| SCHEMBL3466246 | 0.80 | GRM5 (0.37) | PDE4DPDE4BGRM5ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2628727-A2 | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders | Decode Genetics EHF (IS) | 2013-08-21 | — | — | EP | disclosed |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DeCODE Genetics enf (IS) | 2012-08-23 | — | — | US | disclosed |
| EP-2222639-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | Decode Genetics EHF (IS) | 2010-09-01 | — | — | EP | disclosed |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | US | disclosed |
| WO-2009067621-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | PDE4D 7/4885PDE4B 2/4885GRM5 2332/4885 |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | PDE4D 7/4885PDE4B 2/4885GRM5 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.